Advances in Dermatology: 2023 in Review
Advances in Dermatology: 2023 in Review Cather McKay MD, FAAD This year has been yet another exciting year in the field of dermatology with some of the highlights detailed below. Atopic dermatitis, prurigo nodularis, and urticaria The American Academy of Dermatology published guidelines for the management of atopic dermatitis (AD) in adults with topical, light, and systemic therapies this year. 1,2 Topical therapies first used in psoriasis are showing promise in AD. Phosphodiesterase-4 (PDE4) inhibitor roflumilast cream 0.15% (Zoryve) has data available for ages 6 years and up, 3 and a 0.05% cream is proving safe and effective in phase 3 trials for ages 2-5 years. 4 Tapinarof 1% cream (Vtama) is being studied for patients down to the age of 2 years. 5 The indication for oral abrocitinib (Cibinqo) was lowered to the age of 12 this year. Oral baricitinib (Olumiant) is currently approved for alopecia areata in the US but may gain an indication for AD in the...